Viewing data from:

ENALAPRIL MALEATE

ANDA

ENALAPRIL MALEATE | A075048 | CHARTWELL RX SCIENCES LLC

4 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Enalapril Maleate (2023)

Total Spending

$53.7M

Total Claims

2,055,500

Beneficiaries

482,684

Avg Cost/Unit

$0.27

Spending Trend

$90.5M(2019)→$71.2M(2020)→$57.1M(2021)→$50.9M(2022)→$53.7M(2023)

YoY Change:+11.0%

5yr CAGR:-7.6%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs12 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

FARMHISPANIA SAENALAPRIL MALEATE

DMF 115251995

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDENALAPRIL MALEATE USP

DMF 143551999

NEULAND LABORATORIES LTDENALAPRIL MALEATE

DMF 154342001

NEULAND LABORATORIES LTDENALAPRIL MALEATE USP

DMF 199842006

SRI KRISHNA PHARMACEUTICALS LTDENALAPRIL MALEATE USP PROCESS-II

DMF 402112024

MERCK RESEARCH LABORATORIES DIV MERCK CO INCInactiveENALAPRIL MALEATE & DILTIAZEM ER TABLETS

DMF 111701994

MAPRIMED SAInactiveENALAPRIL MALEATE

DMF 116561995

ESTEVE QUIMICA SAInactiveENALAPRIL MALEATE

DMF 118661996

WOCKHARDT LTDInactiveENALAPRIL MALEATE

DMF 127801997

KRKA DD NOVO MESTOInactiveENALAPRIL MALEATE

DMF 128091997

GEDEON RICHTER LTDInactiveENALAPRIL MALEATE

DMF 129391998

MEDICHEM SAInactiveENALAPRIL MALEATE

DMF 130551998

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveENALAPRIL MALEATE USP

DMF 138201998

CHEMSOURCE CORPInactiveENALAPRIL MALEATE DRUG SUBSTANCE

DMF 149382000

PHARMACEUTICAL WORKS POLPHARMA SAInactiveENALAPRIL MALEATE

DMF 189502005

APOTEX PHARMACHEM INDIA PVT LTDInactiveENALAPRIL MALEATE USP

DMF 190582005

MAPRIMED SAInactiveENALAPRIL MALEATE

DMF 203172007

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Jun 24, 2004	ORIG -1	View Letter (PDF)
Aug 22, 2000	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — 2.5MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Aug 22, 2000

No patent or exclusivity listings for this strength.

#002 — 5MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Aug 22, 2000

#003 — 10MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Aug 22, 2000

#004 — 20MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Aug 22, 2000